Drug intelligence / Profile preview

GCC CAR-T

Development stage: Preclinical
Lead developer: Liminatus Pharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GCC CAR-T is a preclinical-stage chimeric antigen receptor (CAR-T) cell therapy being developed by Liminatus Pharma for the treatment of cancer. The therapy originated from research at Thomas Jefferson University. It is designed to target Guanylate Cyclase C (GCC), a protein expressed on certain cancer cells. Liminatus Pharma is advancing GCC CAR-T towards first-in-human clinical trials, with its development being funded through a business combination agreement with Iris Acquisition Corp.

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on GCC CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCC CAR-T.

Explore the full profile